Corrigendum: Ablation of amyloid precursor protein increases insulin-degrading enzyme levels and activity in brain and peripheral tissues (Am J Physiol Endocrinol Metab, (2019) 316, (E106-E120), 10.1152/ajpendo.00279.2018)

  • J. A. Kulas
  • , W. F. Franklin
  • , N. A. Smith
  • , G. D. Manocha
  • , K. L. Puig
  • , K. Nagamoto-Combs
  • , R. D. Hendrix
  • , G. Taglialatela
  • , S. W. Barger
  • , C. K. Combs

Research output: Contribution to journalComment/debate

Abstract

Ablation of amyloid precursor protein increases insulin-degrading enzyme levels and activity in brain and peripheral tissues. Am J Physiol Endocrinol Metab 316: E106–E120, 2019. First published November 13, 2018; doi:10.1152/ajpendo.00279.2018.—In DISCLOSURES, the following statement was omitted in error: “S. W. Barger receives royalties from Merck/Sigma-Aldrich for the sales of secreted amyloid precursor protein.”

Original languageEnglish
Pages (from-to)E345
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume316
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Dive into the research topics of 'Corrigendum: Ablation of amyloid precursor protein increases insulin-degrading enzyme levels and activity in brain and peripheral tissues (Am J Physiol Endocrinol Metab, (2019) 316, (E106-E120), 10.1152/ajpendo.00279.2018)'. Together they form a unique fingerprint.

Cite this